Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Literature DB >> 19959199

Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Ryuta Sakuma¹, Toshie Sakuma, Seiga Ohmine, Robert H Silverman, Yasuhiro Ikeda.

Abstract

The xenotropic murine leukemia virus-related virus (XMRV) is a human retrovirus, recently isolated from tissues of prostate cancer patients with impaired RNase L activity. In this study, we evaluated 10 licensed anti-HIV-1 compounds for their activity against XMRV, including protease inhibitors (PI), nucleoside reverse transcriptase (RT) inhibitors (NRTI), non-nucleoside RT inhibitors (NNRTI) and an integrase inhibitor. No PI affected XMRV production; even high concentrations of Ritonavir failed to inhibit the maturation of XMRV Gag polyproteins. Among the NRTI, NNRTI and integrase inhibitors used in this study, only AZT blocked XMRV infection and replication through inhibition of viral reverse transcription. This sensitivity of XMRV to AZT may be explained by the modest homology in the motif D sequences of HIV-1 and XMRV reverse transcriptases. If XMRV becomes established as an etiological agent for prostate cancer or other diseases, AZT may be useful for preventing or treating XMRV infections in humans. Copyright 2009 Elsevier Inc. All rights reserved.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2009 PMID： 19959199 PMCID： PMC2821880 DOI： 10.1016/j.virol.2009.11.013

Source DB: PubMed Journal: Virology ISSN： 0042-6822 Impact factor: 3.616

52 in total

1. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors: J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal: Antimicrob Agents Chemother Date: 1992-01 Impact factor: 5.191

2. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Authors: A Molla; M Korneyeva; Q Gao; S Vasavanonda; P J Schipper; H M Mo; M Markowitz; T Chernyavskiy; P Niu; N Lyons; A Hsu; G R Granneman; D D Ho; C A Boucher; J M Leonard; D W Norbeck; D J Kempf
Journal: Nat Med Date: 1996-07 Impact factor: 53.440

Review 3. Leukemogenesis by Moloney murine leukemia virus: a multistep process.

Authors: H Fan
Journal: Trends Microbiol Date: 1997-02 Impact factor: 17.079

4. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors: D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal: Proc Natl Acad Sci U S A Date: 1995-03-28 Impact factor: 11.205

5. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors: C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal: Science Date: 1995-11-17 Impact factor: 47.728

6. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines.

Authors: C Strahl; E H Blackburn
Journal: Mol Cell Biol Date: 1996-01 Impact factor: 4.272

7. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

Authors: S D Young; S F Britcher; L O Tran; L S Payne; W C Lumma; T A Lyle; J R Huff; P S Anderson; D B Olsen; S S Carroll
Journal: Antimicrob Agents Chemother Date: 1995-12 Impact factor: 5.191

8. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.

Authors: S F Lacey; B A Larder
Journal: J Virol Date: 1994-05 Impact factor: 5.103

9. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors: T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal: Proc Natl Acad Sci U S A Date: 1995-03-14 Impact factor: 11.205

10. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.

Authors: Z Gu; R S Fletcher; E J Arts; M A Wainberg; M A Parniak
Journal: J Biol Chem Date: 1994-11-11 Impact factor: 5.157

25 in total

1. Absence of detectable xenotropic murine leukemia virus-related virus in plasma or peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected blood donors or individuals in Africa.

Authors: Shixing Tang; Jiangqin Zhao; Ragupathy Viswanath; Phillipe N Nyambi; Andrew D Redd; Armeta Dastyar; Lisa A Spacek; Thomas C Quinn; Xue Wang; Owen Wood; Durga Gaddam; Krishnakumar Devadas; Indira K Hewlett
Journal: Transfusion Date: 2010-11-15 Impact factor: 3.157

2. Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein.

Authors: Toshie Sakuma; Suk See De Ravin; Jason M Tonne; Tayaramma Thatava; Seiga Ohmine; Yasuhiro Takeuchi; Harry L Malech; Yasuhiro Ikeda
Journal: Hum Gene Ther Date: 2010-09-17 Impact factor: 5.695

Xenotropic murine leukemia virus-related virus is susceptible to AZT.

1. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

2. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Review 3. Leukemogenesis by Moloney murine leukemia virus: a multistep process.

4. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

5. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

6. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines.

7. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

8. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.

9. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

10. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.

1. Absence of detectable xenotropic murine leukemia virus-related virus in plasma or peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected blood donors or individuals in Africa.

2. Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein.

3. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

4. The path well traveled: using mammalian retroviruses to guide research on XMRV.

Review 5. Management of prostate cancer in HIV-positive patients.

6. Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome.

7. Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari.

8. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

9. Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

10. Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands.